Apr 17 |
Clearmind signs agreement for psychedelic compounds for mental disorders treatment
|
Apr 17 |
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
|
Apr 9 |
Clearmind Medicine CEO Issues Letter to Shareholders
|
Mar 30 |
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
|
Mar 27 |
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
|
Mar 20 |
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
|
Mar 19 |
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
|
Mar 16 |
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
|
Mar 13 |
Clearmind Medicine receives nod for delisting of shares from Canadian Securities Exchange
|
Mar 13 |
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
|